MedTrace Logo

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

NCT06585007 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2024-09-05

No results posted yet for this study

Summary

Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.

Conditions

  • Castration-resistant Prostate Cancer
  • Oligoprogressive

Interventions

RADIATION

Radiotherapy

Progression-directed therapy (stereotactic body radiation therapy)

PROCEDURE

metastasectomy

Progression-directed therapy (metastasectomy)

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Gert De Meerleer, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-19
Primary Completion
2029-01-20
Completion
2029-01-20

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06585007 on ClinicalTrials.gov